Colorectal cancer metastatic
RecruitingStudy Comparing FOLFIRI with Cetuximab or Bevacizumab for First-Line Treatment in Patients with Metastatic Colorectal Cancer and Specific Genetic Profiles
Study Comparing FOLFIRI with Cetuximab or Bevacizumab for First-Line Treatment in Patients with Metastatic Colorectal Cancer and Specific Genetic Profiles
- Disease:Colorectal cancer metastatic
- Substances:BevacizumabCalcium Folinate+3
Italy- Participants:18–64 years · 65+ years
- Substances:Bevacizumab
- Sponsor:Azienda USL IRCCS Di Reggio Emilia

